<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Vasodilators: antihypertensive; Antihypertensives: vasodilator; Diazoxide: hypertension; Hydralazine; Sodium nitroprusside; Nitroprusside see Sodium nitroprusside; Minoxidil: hypertension; Pulmonary: hypertension; Hypertension: pulmonary; Ambrisentan; Bosentan; Iloprost; Sildenafil: pulmonary hypertension; Tadalafil: pulmonary hypertension; Epoprostenol; Systemic sclerosis; Digital ulcer disease; Sitaxentan" /><meta name="IX" content="Vasodilators: antihypertensive; Antihypertensives: vasodilator; Diazoxide: hypertension; Hydralazine; Sodium nitroprusside; Minoxidil: hypertension; Pulmonary: hypertension; Hypertension: pulmonary; Ambrisentan; Bosentan; Iloprost; Sildenafil: pulmonary hypertension; Tadalafil: pulmonary hypertension; Epoprostenol; Systemic sclerosis; Digital ulcer disease; Sitaxentan" /><meta name="IXN" content="Nitroprusside see Sodium nitroprusside" /><title>2.5.1 Vasodilator antihypertensive drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="2535.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="2535.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=2535.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2534.htm">2.5 Hypertension and heart failure</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2534.htm" title="Previous: 2.5 Hypertension and heart failure">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="201149.htm" title="Next: AMBRISENTAN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_2535">2.5.1 Vasodilator antihypertensive drugs</h1><?highlighter on?><div id="pC" class="jN"><div><p>Vasodilators have a potent hypotensive effect, especially when used
in combination with a beta-blocker and a thiazide. <b>Important:</b> for a warning on the hazards of a very rapid fall in blood pressure,
see <a title="target-block: Accelerated or very severe hypertension" href="2534.htm#_2534.4">Hypertensive crises</a>.</p><p><b>Diazoxide</b> has been used by intravenous injection in hypertensive
emergencies, however alternative treatments are preferred (<a title="BNF:target-block: Accelerated or very severe hypertension" href="2534.htm#_2534.4">see section 2.5</a>)</p><p><b>Hydralazine</b> is given by mouth as an adjunct to other antihypertensives for the
treatment of resistant hypertension but is rarely used; when used
alone it causes tachycardia and fluid retention. The incidence of
side-effects is lower if the dose is kept below 100 mg daily, but
systemic lupus erythematosus should be suspected if there is unexplained
weight loss, arthritis, or any other unexplained ill health. </p><p><b>Sodium nitroprusside</b> [unlicensed] is given by intravenous
infusion to control severe hypertensive emergencies when parenteral
treatment is necessary. </p><div id="_2535.1"><p><b>Minoxidil</b> should
be reserved for the treatment of severe hypertension resistant to
other drugs. Vasodilatation is accompanied by increased
cardiac output and tachycardia and the patients develop fluid retention. For this reason the addition of a beta-blocker and
a diuretic (usually furosemide, in high dosage) are mandatory. Hypertrichosis is troublesome and renders this drug unsuitable
for women. </p></div><p><span>Prazosin</span>, <span>doxazosin</span>, and <span>terazosin</span> (<a title=" Alpha-adrenoceptor blocking drugs" href="2563.htm#_2563">section 2.5.4</a>) have alpha-blocking and vasodilator
properties.</p><p><b>Ambrisentan</b>, <b>bosentan</b>, <b>iloprost</b>, <b>sildenafil</b>, and <b>tadalafil</b> are licensed for the treatment of pulmonary arterial hypertension
and should be used under specialist supervision. <b>Epoprostenol</b> (<a title="monograph-family: Epoprostenol" href="2788.htm#_2788">section 2.8.1</a>) can be used in patients with
primary pulmonary hypertension resistant to other treatments. Bosentan
is also licensed to reduce the number of new digital ulcers in patients
with systemic sclerosis
and ongoing digital
ulcer disease.</p><p><b>Sitaxentan</b> has been withdrawn from the market because the benefit
of treatment does not outweigh the risk of severe hepatotoxicity.</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (November 2005) that iloprost (<span class="cZ">Ventavis</span>®) is accepted for restricted use within NHS Scotland in patients
in whom bosentan is ineffective or not tolerated, and should only
be prescribed by specialists in the Scottish Pulmonary Vascular Unit.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (October 2008) that ambrisentan (<span class="cZ">Volibris</span>®) should be prescribed only by specialists in the Scottish Pulmonary
Vascular Unit or other similar specialists.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (January 2010 and February 2011) that sildenafil tablets
(<span class="cZ">Revatio</span>®) should be initiated only by specialists
in the Scottish Pulmonary Vascular Unit or other similar specialists
and that sildenafil injection (<span class="cZ">Revatio</span>®) should
be prescribed only on the advice of specialists in the Scottish Pulmonary
Vascular Unit or the Scottish Adult Congenital Cardiac Service.</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_201149"><a href="201149.htm" title="AMBRISENTAN">AMBRISENTAN</a></li><li id="_119710"><a href="119710.htm" title="BOSENTAN">BOSENTAN</a></li><li id="_2536"><a href="2536.htm" title="DIAZOXIDE">DIAZOXIDE</a></li><li id="_2538"><a href="2538.htm" title="HYDRALAZINE HYDROCHLORIDE">HYDRALAZINE HYDROCHLORIDE</a></li><li id="_128452"><a href="128452.htm" title="ILOPROST">ILOPROST</a></li><li id="_2540"><a href="2540.htm" title="MINOXIDIL">MINOXIDIL</a></li><li id="_129680"><a href="129680.htm" title="SILDENAFIL">SILDENAFIL</a></li><li id="_2542"><a href="2542.htm" title="SODIUM NITROPRUSSIDE">SODIUM NITROPRUSSIDE</a></li><li id="_213710"><a href="213710.htm" title="TADALAFIL">TADALAFIL</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2534.htm">Previous: 2.5 Hypertension and heart failure</a> | <a class="top" href="2535.htm#">Top</a> | <a accesskey="]" href="201149.htm">Next: AMBRISENTAN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>